OraSure's Q2 Revenue Jumped 10%, but This 2% Year-Over-Year Slide Still Decides the Stock

OraSure's Q2 looks better, but the comeback is still unproven

This is the conflict defining OraSure right now: the business looks cleaner, but the turnaround is not yet proven.

A better quarter did not settle the growth question

Q2 showed real operational improvement. Revenue of $30.6 million rose 9.7% sequentially and came in above the company's guidance range, while gross margin improved. That kind of progress helps keep investors engaged.

The harder question remains. OraSure was still down 2% from a year earlier, so the market is still judging whether this quarter marks the start of durable growth or simply a neater quarter inside a business that has not fully recovered.

The profitability debate is even clearer. OraSure reported GAAP operating income of $5.4 million, but that swing was driven mainly by a $22.6 million reduction in acquisition-related contingent consideration. Beneath that item, the company still posted a non-GAAP operating loss of $14.7 million. In other words, the quarter looked cleaner, but the core business still has not yet proved it can generate consistent operating profit on its own.

The bull case rests on operational repair, not a finished turnaround

The bullish view does not require OraSure to look fixed already. It only requires evidence that the existing business is getting better in a repeatable way.

Margin progress is the clearest positive signal

Two quarters in a row, OraSure has improved at the margin. In Q1, revenue of $27.9 million landed above the midpoint of the company's guidance range. Q2 then repeated the pattern, with revenue of $30.6 million again above guidance and gross margin improving further.

That matters because margin expansion suggests the company is getting more out of its manufacturing base even before growth fully reaccelerates. If revenue can stabilize or improve from here, even modest margin progress can give management more room to cut costs and fund growth without turning to outside capital.

New product milestones matter only if they convert into sales

Management also highlighted FDA clearance of Colli-Pee™•Dx and FDA Emergency Use Authorization of the OraQuick™ Ebola 2.0 Rapid Antigen Test as key innovation milestones.

Those approvals matter because they can broaden OraSure's portfolio beyond the products and programs that have dominated recent revenue. But they do not help the stock by themselves. The real test is whether they lead to distribution, repeat orders, and measurable revenue contribution over the next several quarters.

Repair work shows up first: cleaner metrics, but not yet a strong growth story

Better is not the same as strong, and OraSure's quarter still looks more like repair work than a clean expansion.

Core revenue is the key watchpoint

Gross margin improved again, but the underlying sales base is still soft. Core business revenue was essentially unchanged at $30.6 million, while COVID-19 and Risk Assessment Testing revenue fell to almost zero.

That is why the quarter cuts two ways. The business is getting more efficient, but it has not yet shown the kind of core demand growth that would make the turnaround feel durable.

The loss still matters more than the GAAP headline

The same accounting point keeps coming back. OraSure's GAAP profitability was helped materially by the contingent consideration remeasurement, while the non-GAAP operating loss remained large at $14.7 million.

That keeps the focus on the core business. Margin improvement is encouraging, but until revenue growth returns and operating losses narrow more meaningfully, the turnaround case still rests on promise rather than confirmation.

What decides the next move for OSUR

The question is no longer whether the quarter looked cleaner. It is whether the next few quarters show that the cleanup is turning into a more sustainable earnings path.

Two triggers matter most

First, OraSure needs revenue growth that does not depend on one-off accounting relief. Management has pointed to FDA clearance of Colli-Pee•Dx and the Ebola 2.0 authorization, but investors need to see those milestones convert into real commercial traction.

Second, the company needs to keep reducing operating waste. OraSure entered 2026 with a strong balance sheet, and Q2 did not change that basic strength. If revenue improves while spending stays disciplined, the upside case becomes easier to underwrite.

The main invalidation signal

The main warning sign is simple: another quarter in which core revenue stays flat and reported profitability still leans heavily on the contingent consideration remeasurement.

That is the current positioning lens for OraSure: improving, but still waiting for proof that the business can grow reliably without the cleaner quarter doing most of the talking.